evipedia.ai
← Back

Topical NMN for Hair Regrowth

Evidence Review created on 09/26/2026 using AI4L / Opus 5.5

Also known as: Topical Nicotinamide Mononucleotide, Nicotinamide Mononucleotide, NMN, β-NMN, β-Nicotinamide Mononucleotide, Beta-Nicotinamide Mononucleotide

Motivation

Nicotinamide mononucleotide (NMN) is a vitamin B3–derived molecule that cells turn into a helper compound needed for energy production and cellular repair. Levels of that helper compound fall with age, and hair follicles are among the most energy-demanding structures in the body. Applying NMN directly to the scalp is marketed as a way to deliver it to follicles without losing most of it in the gut and liver.

Interest grew after laboratory and animal studies suggested that NMN could counter hormone-driven follicle shrinkage and protect the stem cells that restart hair growth, and after a study of oral NMN without a comparison group reported thicker hair in middle-aged women. Scalp serums containing NMN are now widely sold, while long-established hair-loss treatments remain the natural point of comparison.

This review examines whether topical NMN regrows hair in adults concerned about thinning, how strong and how independent the evidence is, which risks and trade-offs apply, and how it relates to proven options.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and primary research that discuss NMN and hair growth, the enzyme pathway through which NMN is proposed to act on follicles, how NMN penetrates skin, or the hair-regrowth treatments it competes with.

No content on topical NMN for hair was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine; Huberman’s hair-loss episode is listed for the treatment category, while Attia’s and Patrick’s hair-loss content is member-only. Lifespan.io mentions the 2024 mouse study only in a one-sentence monthly news roundup, too brief to qualify, and its general NMN guide does not address hair.

Grokipedia

  • Nicotinamide mononucleotide

    An AI-generated encyclopedia overview of NMN chemistry, oral human trials, and regulatory history; it does not address scalp application or hair growth.

Examine

  • Nicotinamide Mononucleotide

    An evidence summary of oral NMN dosing, human outcomes, and safety that stresses that longevity effects seen in animals remain unproven in humans; it contains no topical or hair data.

ConsumerLab

Systematic Reviews

This section lists systematic reviews on oral NMN safety, NAD+ precursor outcomes, and the proven hair-loss treatments against which NMN competes.

No systematic review or meta-analysis has examined NMN, topical or oral, for hair growth, so the claimed effect is unrepresented here.

Mechanism of Action

Cells convert NMN into NAD+ via NMNAT enzymes (which attach adenine to NMN). NAD+ powers mitochondria (cellular energy generators) and sirtuins (NAD+-dependent enzymes that tune gene activity and stress responses).

  • Androgen pathway: In dermal papilla cells (signalling cells at the follicle base) exposed to DHT (dihydrotestosterone, the hormone behind pattern hair loss), NMN lowered AR (androgen receptor) and DKK-1 (a protein that pushes follicles into regression), raised β-catenin (the signal of the Wnt pathway, which switches follicles into growth) and VEGF (vascular endothelial growth factor, which builds blood vessels), and damped NF-κB (a master inflammation switch) (Xu et al., 2024).
  • Stem-cell activation: SIRT7 is required for follicles to leave their resting phase and falls with age (Li et al., 2020); NMN restored SIRT7 in damaged follicle stem cells (Cao et al., 2026).
  • Competing view: Extra NAD+ amplifies inflammatory secretions of senescent (permanently arrested) cells (Nacarelli et al., 2019), and in aged pigment cells NMN suppressed Wnt signalling (Brito et al., 2022), opposing the growth signal above.

Pharmacology: NMN is small (334 daltons) but water-soluble and charged, so it crosses intact skin poorly; a membrane model placed it in the upper dermis (Betsuno et al., 2025). It has no receptor selectivity; no human half-life is established. In mice, oral NMN reaches blood within minutes and raises tissue NAD+ within 15 minutes (Mills et al., 2016); surplus breaks down to nicotinamide, tagged by NNMT (a liver enzyme marking nicotinamide for excretion), and cleared in urine.

Historical Context & Evolution

NMN was originally characterized as an intermediate in NAD+ synthesis and had no therapeutic use. Health interest came from ageing biology: mouse work in the 2010s showed that NAD+ declines with age and that long-term oral NMN mitigated age-associated physiological decline (Mills et al., 2016). Oral consumer products followed, and cosmetic makers then added NMN to skin serums on the premise that skin delivery bypasses breakdown in the gut and liver.

Hair entered the picture indirectly. Topical niacin esters, which the body also turns into NAD+, produced a modest fullness gain in a small controlled pilot in women (Draelos et al., 2005). A 2020 mouse study showed that SIRT7 is required for follicle stem cells to leave rest (Li et al., 2020). The first NMN-specific hair study combined hormone-exposed follicle cells with a mouse regrowth model (Xu et al., 2024); cell findings were positive, but mouse regrowth with NMN or minoxidil largely matched untreated controls, so the model could not separate either from no treatment. An uncontrolled oral study from an NMN manufacturer then reported thicker hair (Fukumoto et al., 2025), and work in alopecia areata cells followed (Cao et al., 2026).

What has changed is the volume of preclinical signal, not the class of evidence: no controlled human trial of topical NMN on hair had been published as of September 2026, so the question remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: there is no randomized controlled human trial of topical NMN with a hair count, density, or validated photographic endpoint.

Medium 🟩 🟩

No benefit reaches Medium: not even a single controlled human trial of topical NMN on a hair outcome exists; the only human hair data involve oral NMN or other NAD+ precursors.

Low 🟩

Thicker, Faster-Growing Hair With NAD+ Precursors ⚠️ Conflicted

Indirect human data only. A manufacturer-run, uncontrolled 12-week oral NMN study reported thicker but fewer hairs (Fukumoto et al., 2025). Topical niacin esters (Draelos et al., 2005) and a developer-tested blend (Lee et al., 2026) improved fullness or density. Net: weak and not topical-NMN-specific.

Magnitude: Oral NMN raised hair diameter from 75.3 to 78.8 µm and growing-hair density from 55.9 to 87.7 per cm² over 12 weeks without a placebo group; topical niacin esters increased fullness versus placebo (P = 0.04, the probability of a chance finding), with no effect size reported in the abstract.

Speculative 🟨

Reversal of Androgen-Driven Follicle Shrinkage ⚠️ Conflicted

In hormone-exposed follicle cells, NMN matched minoxidil on growth signals (Xu et al., 2024). Authors claim mouse reversal, yet NMN- and minoxidil-treated mice regrew like untreated controls. Basis is cell and animal data. Net: unproven.

Protection and Activation of Follicle Stem Cells

NMN restored SIRT7 and stem-cell survival in alopecia areata cells and damaged mouse follicles (Cao et al., 2026). The basis is mechanistic and animal work only.

Scalp Skin Collagen Support ⭕️ Not Central to Hair Regrowth

NMN raised collagen output in cultured collagen-making skin cells and crossed a model skin membrane (Betsuno et al., 2025). This bears on scalp skin ageing, not hair regrowth. Basis is laboratory data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in the AR gene (which builds the androgen receptor) drive strong hormone sensitivity in pattern hair loss; any androgen-pathway benefit from NMN would be most tested, and most likely outmatched, in carriers. No variant predicting NMN response is known.
  • Baseline biomarkers: Low ferritin (iron stores), thyroid dysfunction, or vitamin D deficiency cause shedding that NMN cannot correct. Lower baseline NAD+ may leave more room for benefit, but no study has tested this.
  • Sex differences: The only human NMN hair data come from middle-aged women; female pattern thinning is more diffuse and less androgen-dominant. No male data exist for NMN.
  • Pre-existing conditions: Alopecia areata is the only condition with NMN-specific laboratory data. Telogen effluvium (stress-triggered shedding) usually resolves alone, confounding apparent benefit; scarring alopecias (hair loss in which scar tissue replaces follicles) are not expected to respond.
  • Age: Older adults have lower tissue NAD+ and less SIRT7 in follicle stem cells, a theoretical case for greater benefit; however, long-miniaturized follicles at the older end of the range may be beyond rescue.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled human trial of topical NMN has recorded adverse events, and oral trials show no replicated harm.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or consistent observational dataset documents an adverse event from scalp or oral NMN.

Low 🟥

Scalp Irritation, Redness, or Itching

Any leave-on scalp product can irritate, and vehicles often contain alcohol or penetration enhancers. A 24-week trial of a topical NAD+ precursor blend reported no adverse effects (Lee et al., 2026). Irritation from NMN itself has not been studied.

Magnitude: Not quantified in available studies. No trial of topical NMN has recorded scalp adverse events.

Systemic Effects From Absorbed NMN

Scalp application is expected to deliver far less NMN into the body than oral dosing. Oral NMN at 250–2,000 mg/day for up to 24 weeks did not raise adverse events or liver enzymes versus placebo (Yang et al., 2026). Long-term data are lacking.

Magnitude: Adverse-event rates were not higher than placebo across 10 oral trials of up to 24 weeks; the meta-analysis abstract reports no pooled risk figure.

Hair Shedding

In the uncontrolled oral NMN hair study, counted hairs fell; authors blamed seasonal shedding (Fukumoto et al., 2025). A manufacturer-run 4-week placebo-controlled trial of 1,250 mg/day found no safety signal but did not measure hair (Fukamizu et al., 2022). Whether NMN causes shedding remains unconfirmed.

Magnitude: Hair count fell from about 191 to 168 per cm² over 12 weeks of oral NMN, with no placebo group for comparison.

Delayed Use of Proven Hair-Loss Treatments

Pattern hair loss progresses without effective treatment, and long-miniaturized follicles may not recover. Minoxidil, finasteride, and low-level laser therapy each beat placebo in pooled randomized trials (Adil & Godwin, 2017); topical NMN has no such evidence.

Magnitude: Not quantified in available studies. No study has measured hair lost by people using NMN in place of proven treatments.

Speculative 🟨

Amplified Inflammation From Aged Cells

Higher NAD+ strengthened the inflammatory secretions of senescent cells, which can promote tumours (Nacarelli et al., 2019). Basis is mechanistic cell and mouse work; scalp relevance is unknown.

Reduced Pigment Production

NMN cut melanin (pigment) output in aged human pigment cells and reconstructed skin (Brito et al., 2022). Whether scalp use lightens hair is untested; basis is laboratory data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to alter topical NMN safety. Variation in NNMT activity changes how quickly absorbed NMN is cleared, of minor relevance at topical doses.
  • Baseline biomarkers: No biomarker predicts scalp tolerance. Abnormal liver enzymes warrant caution only if combining topical with high-dose oral NMN.
  • Sex differences: No sex-specific risks are documented; pregnancy and breastfeeding lack any safety data.
  • Pre-existing conditions: Seborrheic dermatitis (flaky, inflamed scalp), psoriasis, eczema, or broken scalp skin raise irritation and absorption. A history of scalp skin cancer makes the theoretical inflammation concern more relevant.
  • Age: Thinner, drier scalp skin in older adults increases irritation risk; older adults also have more senescent cells, making the theoretical inflammation concern more relevant.

Key Interactions & Contraindications

  • Topical minoxidil (prescription or over-the-counter): Caution. No interaction data; layering two leave-on products may increase irritation or dilute each. Mitigation: applying minoxidil first, letting it dry, and patch-testing the combination.
  • 5-alpha-reductase inhibitors (finasteride, dutasteride; drugs that block testosterone conversion to DHT): Monitor. No known interaction; possible additive androgen-pathway effect is theoretical. Mitigation: none beyond standard monitoring of the prescription drug.
  • Topical retinoids (tretinoin, adapalene; vitamin A–derived skin drugs): Caution. Increased irritation and scalp barrier disruption, which also raises NMN absorption. Mitigation: separate application times (retinoid at night, NMN in the morning).
  • PARP inhibitors (olaparib, niraparib; cancer drugs that block a DNA-repair enzyme that consumes NAD+): Caution. Theoretical interference with NAD+-targeting cancer therapy. Mitigation: review by the treating oncologist before use.
  • Over-the-counter salicylic acid or ketoconazole shampoos: Monitor. Exfoliating or medicated shampoos can increase scalp sensitivity. Mitigation: alternate-day shampoo use, with NMN applied to dry, intact scalp.
  • Oral NAD+ precursor supplements (NMN, nicotinamide riboside, niacin): Monitor. Additive NAD+ load; niacin adds flushing. Mitigation: accounting for total NAD+ precursor intake and not stacking multiple high-dose products.
  • Other topical NAD+ boosters (niacinamide serums): Monitor. Additive NAD+ supply with possible irritation from multiple actives. Mitigation: introducing one product at a time, four weeks apart.
  • Microneedling: Caution. Greatly increases NMN delivery and irritation or infection risk. Mitigation: a 24-hour gap between microneedling and NMN application, with sterile products only.

Populations who should avoid Topical NMN:

  • Pregnant or breastfeeding women (no safety data)
  • People under 18 years of age (no data; pattern hair loss rarely requires it)
  • People with active scalp dermatitis, psoriasis flares, open wounds, or infection
  • People with active cancer or cancer treatment within the past 12 months, especially on PARP inhibitors, unless cleared by their oncologist
  • People with known hypersensitivity to NMN or other product ingredients

Risk Mitigation Strategies

  • Patch testing before scalp use: A small amount applied behind the ear or on the forearm daily for 3–7 days before full application detects irritation or allergy.
  • Dry, intact scalp only: Avoiding broken, inflamed, or freshly microneedled skin (for at least 24 hours) limits irritation and unintended systemic absorption.
  • Keeping proven treatments in place: Using NMN as an add-on to minoxidil, finasteride, or laser therapy rather than a replacement prevents progressive follicle loss while NMN remains unproven.
  • Baseline photographs and counts: Standardized scalp photos at baseline and every 3 months detect shedding or lack of response early, preventing prolonged use of an ineffective product.
  • Limiting total NAD+ precursor load: When oral NMN is also used, keeping intake within studied ranges (250–1,250 mg/day) stays within documented systemic safety data.
  • Oncologist input where relevant: For people with active or recent cancer, oncologist review before use addresses the theoretical inflammation and tumour-support concern.

Therapeutic Protocol

  • Standard protocol: No clinician or clinic has published a topical NMN hair protocol. The only hair-specific concentration tested is 0.5% NMN applied daily in mice; commercial scalp serums often combine NMN with other actives at undisclosed concentrations.
  • Competing approaches: Topical NMN alone, topical NMN added to minoxidil or finasteride, and oral NMN (500 mg/day in the only human hair study, Fukumoto et al., 2025). None has comparative human data or a named expert or clinic.
  • Application and timing: Once or twice daily to dry scalp is typical by analogy with other leave-on hair products. Evening application allows longer contact without washing; no timing study exists.
  • Half-life: No scalp half-life has been measured. Absorbed NMN is converted to NAD+ within minutes in animal tissue, and NMN in a cosmetic base degrades with a half-life of about seven months at 20 °C.
  • Single versus split dosing: With no data on scalp absorption or clearance, twice-daily application is a practical way to maintain scalp exposure; once daily is the regimen used in mice.
  • Genetic polymorphisms: No variant guides NMN dose. Strong family history of pattern hair loss, reflecting AR gene variants, signals androgen-driven loss, for which androgen-blocking treatments have stronger evidence than NMN.
  • Sex differences: Human hair data exist only for women (oral NMN). Men with androgen-driven loss have stronger evidence for finasteride; women often pair topicals with minoxidil.
  • Age: Adults at the older end of the range have lower NAD+ and less SIRT7 activity, a theoretical rationale for use, but also more follicles miniaturized beyond rescue; earlier use in thinning is more plausible.
  • Baseline biomarkers: Low ferritin, thyroid dysfunction, or low vitamin D can mimic age-related thinning; correcting such deficiencies may regrow hair independently of NMN.
  • Pre-existing conditions: Alopecia areata, telogen effluvium, and scarring alopecias differ in cause and outlook, so response depends on the underlying diagnosis; NMN data in alopecia areata are laboratory-only.

Discontinuation & Cycling

  • Duration: Intended as long-term, like other hair-growth topicals; any benefit would be expected to fade after stopping as the hair cycle continues.
  • Withdrawal effects: None documented. Stopping minoxidil causes shedding, but no such effect is known for NMN.
  • Tapering: Not required; NMN can be stopped abruptly.
  • Cycling: No evidence supports cycling. Response is conventionally judged at 6 months, when unchanged photographs indicate non-response.

Sourcing and Quality

  • Correct form: Quality products contain β-NMN, the biologically active form, and state the concentration; many scalp serums list NMN without a percentage.
  • Stability: NMN slowly breaks down to nicotinamide in water-based products (half-life about seven months at 20 °C). Freshly manufactured, refrigerated, or water-free products preserve potency.
  • Delivery vehicle: NMN penetrates skin poorly; liposomal systems (tiny fat-bubble carriers) improved penetration by 16–23% in laboratory tests (Ye et al., 2026). Microneedle delivery remains experimental.
  • Third-party testing: ConsumerLab’s testing found that oral NAD+ booster products contained their listed amounts; comparable testing of scalp products is rare, so certificates of analysis verifying NMN content and purity are the main safeguard.
  • Reputable raw material: Pharmaceutical-grade NMN used in human trials comes from suppliers such as Mitsubishi Corporation Life Sciences and Abinopharm; compounding pharmacies can prepare defined-concentration solutions from such material.

Practical Considerations

  • Time to effect: Hair cycles are slow; the human NAD+ precursor hair studies ran 12–24 weeks. Hair-growth studies typically assess response only after 3–6 months of consistent use.
  • Common pitfalls: Replacing proven treatments with NMN, buying serums with undisclosed NMN content, applying to wet hair (dilution), and expecting regrowth in areas bald for many years.
  • Regulatory status: NMN is not approved as a hair-loss drug anywhere. In the US, scalp NMN products are sold as cosmetics; the FDA (US Food and Drug Administration) affirmed oral NMN as a lawful supplement ingredient in 2025.
  • Cost and accessibility: NMN serums cost several times more than generic minoxidil. Neither is typically covered by insurers or health systems, so no payer incentive appears to favour either option.

Interaction with Foundational Habits

  • Sleep: Indirect. Oral NMN trials have examined sleep outcomes (Yamaguchi et al., 2024), but topical doses are unlikely to reach systemic levels. Chronic short sleep raises stress hormones that can trigger shedding, so sleep quality is a confounder when judging response.
  • Nutrition: Potentiating, indirect. Adequate protein, iron, zinc, and dietary niacin (meat, fish, legumes) support follicle growth and the body’s own NAD+ production; deficiencies cause shedding that NMN cannot offset. Very low-calorie diets can trigger telogen effluvium.
  • Exercise: Indirect. Exercise raises the body’s NAD+-producing enzyme (Sun et al., 2023) and supports blood flow; no interaction with topical NMN is known. Heavy sweating after application may dilute the product, so applying after exercise and showering is practical.
  • Stress management: Indirect. Psychological stress triggers shedding and inflammation around follicles, which NMN is proposed to damp in laboratory models. Stress-reduction practices remove a common confounder and support any regrowth attempt.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes whether thinning has a correctable cause and creates a reference for judging response. It includes standardized scalp photographs in fixed lighting and part lines, a hair count or density measurement by phototrichogram (software-counted close-up hair photos) where available, and blood tests for iron stores, thyroid function, and vitamin D. Ongoing monitoring repeats photographs and hair counts at 3 months and 6 months, then every 6–12 months while use continues; blood tests are repeated every 6–12 months only if they were abnormal or shedding worsens. A clear gain in density or shaft thickness at 6 months, beyond what proven treatments alone produced, defines success; no change at 6 months is conventionally read as non-response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 50–100 ng/mL for hair growth Low iron stores cause shedding Conventional lower limit is about 15–30 ng/mL; rises with inflammation, so pair with C-reactive protein (an inflammation marker); no fasting needed
TSH 0.5–2.5 mIU/L Thyroid disorders cause diffuse thinning TSH is thyroid-stimulating hormone (the pituitary signal driving the thyroid); conventional range 0.4–4.5 mIU/L; pair with free T4 (the main thyroid hormone); morning draw preferred
25-hydroxyvitamin D 40–60 ng/mL Deficiency is linked to hair loss Conventional sufficiency threshold is 20–30 ng/mL; any time of day
Hair density (phototrichogram) No established target; track change from own baseline Direct measure of regrowth Same scalp site, marked with a tattoo dot or landmark; compare at 3 and 6 months
Hair shaft diameter (trichoscopy) No established target; track change from own baseline Detects thickening before density changes Trichoscopy is magnified scalp imaging; the oral NMN study (Fukumoto et al., 2025) reported about 4 µm gain

Qualitative markers:

  • Hair shed on the pillow and during washing
  • Visible scalp through the part line
  • Hair volume, gloss, and ease of styling
  • Scalp comfort (itching, redness, flaking)

Emerging Research

  • No registered topical NMN hair trial: A ClinicalTrials.gov search on 2026-09-26 found no registered trial of NMN, topical or oral, for hair loss; the case remains preclinical for topical use.
  • Oral NMN ageing trial: NCT06592859, a 240-participant, one-year placebo-controlled trial of 350 mg/day NMN in middle-aged and older adults with biological age as primary endpoint; it could add long-term safety data but does not measure hair.
  • Tracing NMN metabolism: NCT06882096, a 32-participant phase 1 study from an NMN drug developer comparing traceable (isotope-tagged) NMN and nicotinamide in young and older adults; it will clarify how much intact NMN reaches tissues.
  • Replicating the oral hair signal: The uncontrolled oral NMN hair study (Fukumoto et al., 2025) showed thicker shafts but fewer hairs; a placebo-controlled repeat could strengthen or overturn it.
  • Skin delivery systems: Fat-bubble carrier gels (Ye et al., 2026) and NMN-coated microneedles (Ali et al., 2024) raise skin delivery; follicle-level NAD+ measurement after scalp use is the missing link.
  • Evidence that could weaken the case: Mouse regrowth with topical NMN, as with minoxidil, matched untreated controls (Xu et al., 2024), and NAD+ can intensify inflammatory signals of aged cells (Nacarelli et al., 2019); independent replication could confirm a null or adverse effect.
  • Alopecia areata mechanism: Stem-cell protection through SIRT7 in patient-derived cells (Cao et al., 2026) is a testable target for autoimmune hair loss.

Conclusion

Topical NMN is a vitamin B3–derived compound applied to the scalp in the hope of recharging a cellular energy molecule that declines with age and that hair follicles rely on heavily. For health-focused adults willing to follow demanding routines, its appeal is a low-risk, longevity-themed add-on for thinning hair.

The benefit case rests on laboratory cells and mice. In those models, NMN dampened hormone-driven follicle damage and protected the stem cells that restart hair growth. Yet in the one animal study using a scalp-style application, regrowth looked much like that of untreated animals, as it also did with a standard hair-loss drug. The human signal comes from related compounds or from oral NMN rather than scalp application, mostly in small studies, some without comparison groups, and one of them also saw fewer hairs.

On risk, scalp use appears gentle: oral NMN has a reassuring short-term safety record, and no scalp-specific harm has been documented. The main practical risk is time lost while proven hair-loss treatments are set aside. Theoretical concerns about feeding inflammation from aged cells and reducing pigment remain unconfirmed.

The evidence is thin, early, and largely produced by NMN makers, product developers, and promotional websites, so independent confirmation is absent. Overall, topical NMN for hair regrowth sits at the stage of an interesting laboratory idea rather than a demonstrated treatment, with uncertainty running in both directions.

Top - Benefits - Risks - Protocol